VC Funding Top Ten — August 16, 2026: AI Dev Tools, Biotech Breakthroughs, Enterprise Automation

Overview

Sunday afternoon, August sixteenth. Today's biggest check goes to Lovable, locking in a four hundred million dollar Series C at a thirteen-point-three billion dollar valuation. Ten rounds crossed the wire today, with capital continuing to flood into AI infrastructure and applications. I'm your Host. With me are our Mar

In this show

• Sunday afternoon, August sixteenth. Today's biggest check goes to Lovable, locking in a four hundred million dollar Series C at a thirteen-point-three billion dollar valuation. Ten rounds crossed the wire today, with capital continuing to flood into AI infrastructure and applications. I'm your Host. With me are our Markets and World correspondents. Let's break down the day's deal flow.
• The final tally shows one-point-zero-nine billion dollars in disclosed funding across those ten deals. The hottest category was AI, accounting for four of the top ten rounds. There were no notable IPOs or M&A announcements today. The story of the day remains the accelerating wave of nine and ten-figure AI funding rounds, with capital now flowing into infrastructure, developer tools, and vertical applications, moving beyond just foundational models.
• Leading the pack is Lovable, with its massive four hundred million dollar Series C. The round was co-led by Menlo Ventures and Scaleup Europe Fund, pushing the company's valuation to thirteen-point-three billion dollars. Lovable develops AI-powered coding and validation tools for developers. This round solidifies its position as one of Europe's most valuable AI startups, showing the intense investor appetite for AI-native tools that automate the software development lifecycle.
• Coming in at number two, HappyRobot secured a one hundred fifty million dollar Series C, making it a new unicorn with a one-point-two billion dollar valuation. Prysm Capital and Eurazeo led the round. The company provides an AI agent platform for logistics and enterprise operations. This new capital is earmarked for expansion beyond freight into sectors like energy, insurance, and telecom, signaling a broad horizontal scaling strategy for its automation tech.
• In biotech, Swiss firm Vaderis Therapeutics raised a one hundred fifty-two million dollar Series B. The round was led by Life Sciences at Goldman Sachs Alternatives, TCGX, and Omega Funds. Vaderis is developing what could be the first treatment for hereditary hemorrhagic telangiectasia, a rare blood vessel disorder. The funding will propel its lead drug candidate, engasertib, through a pivotal Phase 3 trial, addressing a significant unmet medical need.
• Also in biotech, InduPro closed a seventy-seven million dollar Series B led by The Column Group and Vida Ventures. The company develops bispecific antibody-drug conjugates for cancer treatment. Its lead candidate targets non-small cell lung cancer. With a strong syndicate of Big Pharma backers including Merck, Sanofi, and Eli Lilly, InduPro has already dosed the first patient in its Phase 1 trial, showing significant momentum.
• Developer tools continue to attract capital, with Convex raising a fifty-seven million dollar Series B led by Insight Partners. Convex offers a unified backend platform with a reactive database specifically for developers building AI-powered applications. The strong participation from existing investors Andreessen Horowitz and Spark Capital signals high confidence that the platform can capture a growing market of developers working with AI agents and complex data interactions.
• At number six, AI code review platform Blacksmith landed a forty-five million dollar Series B, led by Peak XV Partners. The deal gives the company a five hundred fifty million dollar post-money valuation. This round represents a remarkable tenfold valuation increase since its last funding, highlighting the massive demand from enterprises for AI tools that can enhance developer productivity and ensure higher code quality across the software stack.
• In fintech, Yuno secured its own forty-five million dollar Series B, with Global PayTech Ventures leading. Yuno is building an AI-native operating system for global payments and financial services infrastructure. The participation of heavyweights like Andreessen Horowitz, Tiger Global, and QuantumLight Capital signals a strong investor consensus on the need for an intelligent AI orchestration layer to manage the growing complexity of the global payments landscape.
• AI infrastructure startup Naïve raised twenty-eight-point-five million dollars in a Series A led by Nexus Venture Partners. The company is building a platform to automate business setup and operations through a unified API and serverless stack for what it calls 'autonomous companies.' The company reported a tenfold increase in annual recurring revenue in the six months before the investment, indicating rapid market adoption of its platform for orchestrating AI agents.
• Rounding out our deep dive is Amplifica Holdings Group, a clinical-stage biopharma company, which closed an oversubscribed twenty-six million dollar Series B. Led by Tasso Partners, the round saw participation from Eli Lilly and Company. Amplifica is developing injectable therapies to reactivate dormant hair follicles. The funds will advance clinical development for its novel approach to treating androgenetic alopecia, a market with a huge need for better solutions.
• Looking ahead, the key trend to watch is the rise of AI-native infrastructure. This week's funding for Naïve and Convex shows a clear shift in investment towards the foundational tools for building AI-powered companies. As businesses deploy more autonomous agents, the demand for robust backends and orchestration platforms will only surge. Expect more significant funding in this space as the AI ecosystem matures beyond models to the tools needed to operate at scale. That's our show. We'll be back tomorrow afternoon at three PM Pacific with the next deal flow.